ArticleNucleic acids research2015
DNA targeting by the type I-G and type I-A CRISPR-Cas systems of Pyrococcus furiosus.
Article in Nucleic acids research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 42 citations in OpenAlex.
- Archaeal replicative primase mediates DNA double-strand break repair.Nucleic acids research · 2025Article
- Repurposing Type I-A CRISPR-Cas3 for a robust diagnosis of human papillomavirus (HPV).Communications biology · 2024Article
- Targeted large fragment deletion in plants using paired crRNAs with type I CRISPR system.Plant biotechnology journal · 2023Article
- Histones direct site-specific CRISPR spacer acquisition in model archaeon.Nature microbiology · 2023Article
- Application of the endogenous CRISPR-Cas type I-D system for genetic engineering in the thermoacidophilic archaeonFrontiers in microbiology · 2023Article
- Hyper-stimulation of Pyrococcus furiosus CRISPR DNA uptake by a self-transmissible plasmid.Extremophiles : life under extreme conditions · 2022Article
- Allosteric control of type I-A CRISPR-Cas3 complexes and establishment as effective nucleic acid detection and human genome editing tools.Molecular cell · 2022Article
- Genomic and epigenetic landscapes drive CRISPR-based genome editing inProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- Positioning Diverse Type IV Structures and Functions Within Class 1 CRISPR-Cas Systems.Frontiers in microbiology · 2021Article
- Heavily Armed Ancestors: CRISPR Immunity and Applications in Archaea with a Comparative Analysis of CRISPR Types in Sulfolobales.Biomolecules · 2020Review
- Primed CRISPR DNA uptake in Pyrococcus furiosus.Nucleic acids research · 2020Article
- Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.Nucleic acids research · 2020Article
- Cas3/I-C mediated target DNA recognition and cleavage during CRISPR interference are independent of the composition and architecture of Cascade surveillance complex.Nucleic acids research · 2020Article
- Type I-F CRISPR-Cas Distribution and Array Dynamics inG3 (Bethesda, Md.) · 2020Article
- Endogenous Type I CRISPR-Cas: From Foreign DNA Defense to Prokaryotic Engineering.Frontiers in bioengineering and biotechnology · 2020Review
- CRISPR-Cas3 induces broad and unidirectional genome editing in human cells.Nature communications · 2019Article
- CRISPR repeat sequences and relative spacing specify DNA integration by Pyrococcus furiosus Cas1 and Cas2.Nucleic acids research · 2019Article
- Article
- CRISPR RNA-guided DNA cleavage by reconstituted Type I-A immune effector complexes.Extremophiles : life under extreme conditions · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
CRISPR-Cas systems silence plasmids and viruses in prokaryotes. CRISPR-Cas effector complexes contain CRISPR RNAs (crRNAs) that include sequences captured from invaders and direct CRISPR-associated (Cas) proteins to destroy corresponding invader nucleic acids. Pyrococcus furiosus (Pfu) harbors three CRISPR-Cas immune systems: a Cst (Type I-G) system with an associated Cmr (Type III-B) module at one locus, and a partial Csa (Type I-A) module (lacking known invader sequence acquisition and crRNA processing genes) at another locus. The Pfu Cmr complex cleaves complementary target RNAs, and Csa systems have been shown to target DNA, while the mechanism by which Cst complexes silence invaders is unknown. In this study, we investigated the function of the Cst as well as Csa system in Pfu strains harboring a single CRISPR-Cas system. Plasmid transformation assays revealed that the Cst and Csa systems both function by DNA silencing and utilize similar flanking sequence information (PAMs) to identify invader DNA. Silencing by each system specifically requires its associated Cas3 nuclease. crRNAs from the 7 shared CRISPR loci in Pfu are processed for use by all 3 effector complexes, and Northern analysis revealed that individual effector complexes dictate the profile of mature crRNA species that is generated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.